Author

K. M. Peh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3

Frequent Co-Authors

A. W. Partridge· 3 shared B. Henry· 3 shared S. Lim· 3 shared S. Ng· 3 shared C. J. Brown· 2 shared C. W. Johannes· 2 shared D. P. Lane· 2 shared J. Teo· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

A. W. Partridge

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling

S. Lim, N. Boyer, N. Boo, C. Huang, G. Venkatachalam, Y.-C. A. Juang, M. Garrigou, K. Kaan, K. M. Peh, A. Sadruddin, P. Gopal, R. Duggal, T. Y. Yuen, S. Ng, S. Kannan, , A. W. Partridge

This paper identifies macrocyclic peptides that inhibit KRAS signaling by binding to its hydrophobic pocket, showing on-target activity and improved proteolytic stability.

bioRxiv · Sep 11, 2021Biochemistry

bioPROTACs establish RAS as a degradable target and provide novel RAS biology insights

S. Lim, R. Khoo, Y.-C. Juang, P. Gopal, H. Zhang, C. Yeo, K. M. Peh, J. Teo, S. Ng, B. Henry, A. W. Partridge

The paper demonstrates that RAS proteins can be degraded using bioPROTACs and provides insights into the functional consequences of RAS degradation and mutant susceptibility.

bioRxiv · Jun 26, 2020 · PreprintCancer Biology

bioPROTACs as versatile modulators of intracellular therapeutic targets: Application to proliferating cell nuclear antigen (PCNA)

S. Lim, R. Khoo, K. M. Peh, J. Teo, S. C. Chang, S. Ng, G. L. Beilhartz, R. A. Melnyk, C. W. Johannes, C. J. Brown, D. P. Lane, B. Henry, A. W. Partridge

This paper introduces bioPROTACs as intracellular biologics for targeted protein degradation, demonstrating their effectiveness against PCNA with rapid degradation and functional effects.

Proceedings of the National Academy of Sciences · Mar 2, 2020Peer-reviewedCell Biology